Investigation of Methicillin-resistant Staphylococcus aureus inhibition with gallic acid and linezolid loaded Poly(Ɛ-caprolactone)-Collagen-Xylitol carrier

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) causes serious infections to humans. Combination therapy exhibits good inhibition efficacy against MRSA infections; thus, a natural compound (Gallic acid) and an existing antibiotic drug (Linezolid) combined with Poly(Ɛ-caprolactone)-Collagen-Xylitol (PCX) carrier was designed. Initially, the natural compound was selected from the Natural Product database through molecular docking analysis and the linezolid interaction was investigated against MRSA protein. The binding energies of gallic acid and linezolid was observed as -6.1 kcal/mol and -9.5 kcal/mol against the MRSA (2W9H) strain. The physicochemical characterization confirms the carrier and drug-loaded carrier formation. The biological studies exhibited the potential antibacterial activity of PCXGL against MRSA. PCXGL showed the zone of inhibition and minimum inhibitory concentration of 20 ± 1 mm and 62.5 µg/mL against MRSA, respectively. The minimum bactericidal concentration was obtained as 250 µg/mL, and the ruptured cell morphology was observed through SEM analysis after treating MRSA with PCXGL. It is due to the eradication ability of PCXGL against MRSA. Further, the biofilm inhibition analysis, biofilm dissociation assay, and fluorescence images proved the MRSA biofilm degradation ability of PCXGL. These findings can provide a potential lead for the treatment of MRSA infections.